Singapore, May 5, 2009: China Sky One Medical has announced that the research and development project for the company's Sudden Cardiac Death (SCD) early examination kit has been appraised by the Heilongjiang Bureau of Science and Technology. The R&D project was undertaken jointly by China Sky One Medical and Harbin Medical University.

The team of specialists from the Heilongjiang Bureau of Science and Technology concluded that the research was successful and reliably conducted. As a result, the company is permitted to begin the research and application process for its SCD early examination kit, which will be classified as a national new product under the diagnostic kit category. The appraisal team noted that the success of the project would represent a significant breakthrough in preventing and reducing the threat of SCD.

In order to commercialize SCD diagnostic technology, Harbin Medical University is said to have transferred the patent exclusively to Harbin First Bio-Engineering Company, the wholly owned subsidiary of China Sky One Medical, in early 2009. The two parties will collaborate in researching a production method for the SCD early examination kit that includes large scale clinical trial comparisons. Their research has been going smoothly and according to schedule.

The leader of this project is Prof Baofeng Yang, the Principal of Harbin Medical University, who is also the Chief Scientist of Chinese National 973 Project and Standing Director of the China Pharmaceutical Alliance.

In 2008, Prof Yang and his research team found that the concentration of a substance called "MicroRNA-1" in human blood has positive correlation with the occurrence of SCD. After detailed clinical studies involving many samples, Prof Yang concluded that the existence of MicroRNA-1 in human blood is a useful predictor of SCD, and higher concentrations of MicroRNA-1 means a higher probability of SCD. The discovery was published in the Journal Nature Medicine. In late 2008, Prof Yang received the national patent for this discovery.

"We are proud because this project represents one of the very few proprietary technologies in the bio-diagnostic field that is owned by the Chinese," said Mr Yan-Qing Liu, CEO, China Sky One Medical. "We expect to complete the new product application process within one year. We believe that there is huge market potential for this new product and that revenues could likely reach over $20 million a year."